Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Mid-range Performer
1435.2000 7.30 (0.51%)
NSE Dec 23, 2025 15:31 PM
Volume: 79,812
 

1435.20
0.51%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Q3FY19 results were a comprehensive beat vis-a-vis I-direct estimates on the profitability front due to strong EBITDA margins (24.5% vs. I-direct estimate of 17.7%). Revenues grew 10.3% YoY to | 947.6 crore (I-direct estimate: | 939.1 crore) due to 10% growth in domestic formulations to | 421.6 crore EBITDA margins improved 569 bps YoY to 24.5% (I-direct estimate: 17.7%) due forex gain, strong gross margins and lower employee...
Number of FII/FPI investors decreased from 270 to 254 in Sep 2025 qtr
More from Ipca Laboratories Ltd.
Recommended